| Phase 3 |
| NCT05855200 |
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III… |
Colonic Neoplasms |
Recruiting |
| NCT06256588 |
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally… |
Neoplasms, Head and Neck |
Recruiting |
| NCT03602859 |
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care… |
Ovarian Neoplasms |
Active, Not Recruiting |
| Phase 2 |
| NCT07336147 |
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich… |
Female |
Recruiting |
| NCT05700721 |
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients… |
Brain Metastases |
Recruiting |
| NCT06830239 |
Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage… |
Colon Cancer Stage III |
Recruiting |
| NCT07408063 |
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate… |
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Recruiting |
| NCT06023862 |
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus… |
Ovarian Neoplasms |
Recruiting |
| NCT04165772 |
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair… |
Rectal Adenocarcinoma |
Recruiting |
| NCT04774419 |
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive… |
Endometrial Cancer |
Recruiting |
| NCT06567782 |
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX… |
Neoplasms, Colon |
Recruiting |
| NCT05565378 |
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously… |
Lung Cancer, Non-Small Cell |
Active, Not Recruiting |
| NCT06238635 |
Dostarlimab and Cobolimab in Advanced Cervical Cancer |
Cervical Cancer |
Active, Not Recruiting |
| NCT07381777 |
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard… |
Locally Advanced Rectal Cancer (LARC) |
Not Yet Recruiting |
| NCT04068753 |
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive… |
Recurrent Cervix Cancer |
Active, Not Recruiting |
| NCT05870761 |
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous… |
Recurrent Endometrial Serous Adenocarcinoma |
Active, Not Recruiting |
| NCT04701307 |
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other… |
Lung Small Cell Carcinoma |
Active, Not Recruiting |
| NCT04584255 |
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer |
Stage I Breast Cancer |
Active, Not Recruiting |
| NCT06062420 |
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in… |
Neoplasms, Head and Neck |
Active, Not Recruiting |
| NCT05723562 |
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer |
Neoplasms, Rectal |
Active, Not Recruiting |
| Phase 1/2 |
| NCT06405230 |
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… |
Lung Cancer, Non-Small Cell |
Recruiting |
| NCT06796907 |
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced… |
Tumours, Gynecological |
Recruiting |
| NCT06879717 |
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without… |
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Active, Not Recruiting |
| NCT04126200 |
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer… |
Multiple Myeloma |
Active, Not Recruiting |
| NCT05784012 |
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in… |
Head and Neck Squamous Cell Carcinoma |
Active, Not Recruiting |